Commercial Credit Report for Nugenerex Immuno-Oncology Inc

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Nugenerex Immuno-Oncology Inc is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Nugenerex Immuno-Oncology Inc
10102 USA TODAY WAY
Phone: (617) 699-1965p:617 699-1965	MIRAMAR, FL 33025 United States	Fax: (845) 818-3588f:845 818-3588

On 3/3/2023, the Company was acquired by Beijing Youfeng Biological Technology Co., Ltd.
This company is no longer actively traded on any major stock exchange.

Business Summary

NuGenerex Immuno-Oncology, Inc. is a biotechnology company. The Company is focused on the modulation of the immune system and activation of T cells to treat cancer. It is engaged in developing immunotherapeutic products and vaccines based on its patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The Company’s lead immunotherapy product candidate is AE37, an Ii-Key-HER2 peptide vaccine for breast, prostate, and bladder cancer. AE37, an Ii-Key-HER2 vaccine that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
-	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
4/30/2021	7/31/2020	Yes	Yes	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations
2836	Biological products, except diagnostic substances
8731	Commercial physical and biological research

General Information

Outstanding Shares:	101,196,670	(As of 5/21/2021)
Stock Exchange:	OTC
Federal Tax Id:	043208418
Fax Number:	(845) 818-3588

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN